{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:26:50Z","timestamp":1788690410661,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.beha.2016.08.025","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T08:30:49Z","timestamp":1478248249000},"page":"158-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Marginal zone lymphoma in elderly and geriatric patients"],"prefix":"10.1016","volume":"30","author":[{"given":"Valentin","family":"Goede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2016.08.025_bib1","series-title":"World Health Organization classification of tumours of haematopoietic and lymphoid tissues","first-page":"58","article-title":"Introduction and overview of the classification of the lymphoid neoplasms","author":"Jaffe","year":"2008"},{"key":"10.1016\/j.beha.2016.08.025_bib2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"issue":"Suppl. 6","key":"10.1016\/j.beha.2016.08.025_bib3","article-title":"Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Zucca","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.08.025_bib4","series-title":"National comprehensive cancer network (NCCN) clinical practice guidelines in oncology","article-title":"Non-Hodgkin's lymphomas","author":"Zelenetz","year":"2014"},{"key":"10.1016\/j.beha.2016.08.025_bib5","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.025_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3322\/caac.21330","article-title":"Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","volume":"66","author":"Raderer","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.beha.2016.08.025_bib7","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2015-12-624296","article-title":"Optimizing therapy for nodal marginal zone lymphoma","volume":"127","author":"Thieblemont","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.025_bib8","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood-2015-12-624304","article-title":"The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance","volume":"127","author":"Zucca","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.025_bib9","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A\u00a0clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma","volume":"89","author":"The Non-Hodgkin's Lymphoma Classification Project","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.025_bib10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.27773","article-title":"Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database","volume":"119","author":"Olszewski","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.08.025_bib11","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM199405053301803","article-title":"Helicobacter pylori infection and gastric lymphoma","volume":"330","author":"Parsonnet","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.025_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11864-015-0344-6","article-title":"The role of infectious agents, antibiotics, and antiviral therapy in the treatment of extranodal marginal zone lymphoma and other low-grade lymphomas","volume":"16","author":"Foster","year":"2015","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.beha.2016.08.025_bib13","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2010-01-264275","article-title":"Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome","volume":"117","author":"Rinaldi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.025_bib14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/leu.2014.294","article-title":"The Kruppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma","volume":"29","author":"Piva","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.08.025_bib15","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20120904","article-title":"The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development","volume":"209","author":"Rossi","year":"2012","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.beha.2016.08.025_bib16","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/sj.leu.2404782","article-title":"MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course","volume":"21","author":"Wohrer","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.08.025_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.leukres.2013.12.018","article-title":"The relevance of a geriatric assessment for elderly patients with a haematological malignancy\u2013a systematic review","volume":"38","author":"Hamaker","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2016.08.025_bib18","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2141.2005.05508.x","article-title":"A\u00a0population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index","volume":"129","author":"Janssen-Heijnen","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.08.025_bib19","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/0016-5085(92)91723-H","article-title":"Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis","volume":"102","author":"Radaszkiewicz","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.beha.2016.08.025_bib20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1046\/j.1365-2141.2003.04165.x","article-title":"Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients","volume":"120","author":"Parry-Jones","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.08.025_bib21","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","article-title":"Splenic marginal zone lymphoma: a prognostic model for clinical use","volume":"107","author":"Arcaini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.025_bib22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.12011","article-title":"Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases","volume":"159","author":"Montalban","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.08.025_bib23","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing","volume":"21","author":"Parry","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2016.08.025_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(00)03571-6","article-title":"Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy","volume":"357","author":"Liu","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2016.08.025_bib25","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654","article-title":"Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients","volume":"100","author":"Chacon","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.025_bib26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/10428194.2015.1091933","article-title":"Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group","volume":"57","author":"Goede","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.08.025_bib27","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3324\/haematol.2013.096792","article-title":"Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials","volume":"99","author":"Goede","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.08.025_bib28","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3109\/10428194.2014.935364","article-title":"Prognostic significance of geriatric assessment in combination with laboratory parameters in elderly patients with aggressive non-Hodgkin lymphoma","volume":"56","author":"Aaldriks","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.08.025_bib29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2141.2011.08934.x","article-title":"Analysis of very elderly (>\/=80 years) non-Hodgkin lymphoma: impact of functional status and co-morbidities on outcome","volume":"156","author":"Nabhan","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.08.025_bib30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3960\/jslrt.56.43","article-title":"Retrospective analysis of treatment outcomes and geriatric assessment in elderly malignant lymphoma patients","volume":"56","author":"Naito","year":"2016","journal-title":"J\u00a0Clin Exp Hematop"},{"key":"10.1016\/j.beha.2016.08.025_bib31","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jgo.2015.10.183","article-title":"Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy","volume":"6","author":"Park","year":"2015","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.beha.2016.08.025_bib32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1586\/17474086.2015.1024650","article-title":"Impact of comorbidities on the treatment of non-Hodgkin's lymphoma: a systematic review","volume":"8","author":"Terret","year":"2015","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.beha.2016.08.025_bib33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00432-010-0933-5","article-title":"Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma","volume":"137","author":"Winkelmann","year":"2011","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.025_bib34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjh.12765","article-title":"Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study","volume":"165","author":"Wieringa","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.08.025_bib35","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1634\/theoncologist.2014-0247","article-title":"Geriatric assessment-identified deficits in older cancer patients with normal performance status","volume":"20","author":"Jolly","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.beha.2016.08.025_bib36","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/10428194.2013.788176","article-title":"Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi","volume":"55","author":"Merli","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.08.025_bib37","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1634\/theoncologist.2011-0417","article-title":"Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma","volume":"17","author":"Spina","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.beha.2016.08.025_bib38","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1002\/cncr.24490","article-title":"A\u00a0comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy","volume":"115","author":"Tucci","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.08.025_bib39","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.08.025_bib40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2125.2000.00261.x","article-title":"Macrolide \u2013 induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin","volume":"50","author":"Westphal","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.beha.2016.08.025_bib41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.clon.2014.10.002","article-title":"Outcomes of primary lymphoma of the ocular adnexa (orbital lymphoma) treated with radiotherapy","volume":"27","author":"Woolf","year":"2015","journal-title":"Clin Oncol R Coll Radiol"},{"key":"10.1016\/j.beha.2016.08.025_bib42","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3109\/10428194.2015.1092529","article-title":"Peri-operative complications and hematologic improvement after first-line splenectomy for splenic marginal zone lymphoma","volume":"57","author":"Pata","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.08.025_bib43","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1001\/archsurg.142.11.1072","article-title":"Adverse outcomes of geriatric patients undergoing abdominal surgery who are at high risk for delirium","volume":"142","author":"Ganai","year":"2007","journal-title":"Arch Surg"},{"key":"10.1016\/j.beha.2016.08.025_bib44","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/bjs.5053","article-title":"Postoperative delirium in elderly patients after major abdominal surgery","volume":"92","author":"Olin","year":"2005","journal-title":"Br J Surg"},{"key":"10.1016\/j.beha.2016.08.025_bib45","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.3748\/wjg.v19.i24.3854","article-title":"Laparoscopic splenectomy for treatment of splenic marginal zone lymphoma","volume":"19","author":"Wu","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.beha.2016.08.025_bib46","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00464-005-0125-6","article-title":"Laparoscopic splenectomy in the elderly: a morbid procedure?","volume":"19","author":"Kavic","year":"2005","journal-title":"Surg Endosc"},{"key":"10.1016\/j.beha.2016.08.025_bib47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.seminhematol.2010.01.004","article-title":"Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab","volume":"47","author":"Bennett","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.beha.2016.08.025_bib48","first-page":"856","article-title":"Rituximab monotherapy for splenic marginal zone lymphoma","volume":"90","author":"Bennett","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.08.025_bib49","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.025_bib50","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1634\/theoncologist.2012-0251","article-title":"Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy","volume":"18","author":"Kalpadakis","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.beha.2016.08.025_bib51","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2012.44.7920","article-title":"Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma","volume":"31","author":"Leblond","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.025_bib52","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study","volume":"31","author":"Zucca","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.025_bib53","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-2141.2009.07677.x","article-title":"A\u00a0phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas","volume":"145","author":"Brown","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.08.025_bib54","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.3109\/10428194.2015.1029925","article-title":"Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study","volume":"56","author":"Iannitto","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.08.025_bib55","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00277-011-1337-6","article-title":"Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: consortium for improving survival of lymphoma (CISL) study","volume":"91","author":"Kang","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2016.08.025_bib56","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00277-013-1865-3","article-title":"Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)","volume":"93","author":"Kiesewetter","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2016.08.025_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2334","article-title":"The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma","author":"Laribi","year":"2016","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2016.08.025_bib58","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cncr.24605","article-title":"Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type","volume":"115","author":"Salar","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.08.025_bib59","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3324\/haematol.2012.072587","article-title":"Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie","volume":"98","author":"Troch","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.08.025_bib60","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2016.08.025_bib61","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.025_bib62","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1586\/14737140.2015.1009042","article-title":"Emerging drugs for diffuse large B-cell lymphoma","volume":"15","author":"Mondello","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.beha.2016.08.025_bib63","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2174\/1871523013666140416100814","article-title":"New drugs for follicular lymphoma in older adults","volume":"14","author":"Schmitt","year":"2014","journal-title":"Anticancer Agents Med Chem"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T03:52:49Z","timestamp":1601178769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616300767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":63,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1521692616300767"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.025","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Marginal zone lymphoma in elderly and geriatric patients","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}